This topic contains a solution. Click here to go to the answer

Author Question: The Accounts Receivable T account shows the following 250, debit 1,250, debit 300, credit 250, ... (Read 117 times)

krzymel

  • Hero Member
  • *****
  • Posts: 548
The Accounts Receivable T account shows the following 250, debit 1,250, debit 300, credit 250, credit What is the balance of the account?
 a. 1,500, debit
  b. 550, credit
  c. 950, debit
  d. 950, credit
  e. 2,050, debit

Question 2

(40 min) Variable versus absorption costing.
 
  The Zwatch Company manufactures trendy, high-quality, moderately priced watches. As Zwatch's senior financial analyst, you are asked to recommend a method of inventory costing. The CFO will use your recommendation to prepare Zwatch's 2014 income statement. The following data are for the year ended December 31, 2014:
 
  Required:
  Assume standard costs per unit are the same for units in beginning inventory and units produced during the year. Also, assume no price, spending, or efficiency variances. Any production-volume variance is written off to cost of goods sold in the month in which it occurs.
  1. Prepare income statements under variable and absorption costing for the year ended December 31, 2014.
  2. What is Zwatch's operating income as percentage of revenues under each costing method?
  3. Explain the difference in operating income between the two methods.
  4. Which costing method would you recommend to the CFO? Why?



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

ilianabrrr

  • Sr. Member
  • ****
  • Posts: 332
Answer to Question 1

C

Answer to Question 2

1.

Beginning Inventory + 2014 Production = 2014 Sales + Ending Inventory

85,000 units + 2014 Production = 345,400 units + 34,500 units

2014 Production = 294,900 units

Income Statement for the Zwatch Company, Variable Costing
for the Year Ended December 31, 2014

Revenues: 22  345,400 7,598,800
Variable costs
Beginning inventory: 5.10  85,000  433,500
Variable manufacturing costs: 5.10  294,900 1,503,990
Cost of goods available for sale 1,937,490
Deduct ending inventory: 5.10  34,500 (175,950)
Variable cost of goods sold 1,761,540
Variable operating costs: 1.10  345,400 379,940
Adjustment for variances 0
Total variable costs 2,141,480
Contribution margin 5,457,320
Fixed costs
Fixed manufacturing overhead costs 1,440,000
Fixed operating costs 1,080,000
Total fixed costs 2,520,000
Operating income 2,937,320

Absorption Costing Data

Fixed manufacturing overhead allocation rate =
Fixed manufacturing overhead/Denominator level machine-hours = 1,440,000 6,000
= 240 per machine-hour

Fixed manufacturing overhead allocation rate per unit =
Fixed manufacturing overhead allocation rate/standard production rate = 240 50
= 4.80 per unit

Income Statement for the Zwatch Company, Absorption Costing
for the Year Ended December 31, 2014

Revenues: 22  345,400 7,598,800
Cost of goods sold
Beginning inventory (5.10 + 4.80)  85,000  841,500
Variable manuf. costs: 5.10  294,900 1,503,990
Allocated fixed manuf. costs: 4.80  294,900 1,415,520
Cost of goods available for sale 3,761,010
Deduct ending inventory: (5.10 + 4.80)  34,500 (341,550)
Adjust for manuf. variances (4.80  5,100)a 24,480 U
Cost of goods sold 3,443,940
Gross margin 4,154,860
Operating costs
Variable operating costs: 1.10  345,400  379,940
Fixed operating costs 1,080,000
Total operating costs 1,459,940
Operating income 2,694,920

a Production volume variance = (6,000 hours  50)  294,900  4.80
= (300,000  294,900)  4.80
= 24,480

2. Zwatch's operating margins as a percentage of revenues are

Under variable costing:
Revenues 7,598,800
Operating income 2,937,320
Operating income as percentage of revenues 38.7

Under absorption costing:
Revenues 7,598,800
Operating income 2,694,920
Operating income as percentage of revenues 35.5

3. Operating income using variable costing is about 9 percent higher than operating income calculated using absorption costing.

Variable costing operating income  Absorption costing operating income =
2,937,320  2,694,920 = 242,400

Fixed manufacturing costs in beginning inventory under absorption costing  
Fixed manufacturing costs in ending inventory under absorption costing
= (4.80  85,000)  (4.80  34,500) = 242,400

4. The factors the CFO should consider include
(a) Effect on managerial behavior.
(b) Effect on external users of financial statements.

I would recommend absorption costing because it considers all the manufacturing resources (whether variable or fixed) used to produce units of output. Absorption costing has many critics. However, the dysfunctional aspects associated with absorption costing can be reduced by
 Careful budgeting and inventory planning.
 Adding a capital charge to reduce the incentives to build up inventory.
 Monitoring nonfinancial performance measures.




krzymel

  • Member
  • Posts: 548
Reply 2 on: Jul 6, 2018
:D TYSM


anyusername12131

  • Member
  • Posts: 327
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

Historic treatments for rheumatoid arthritis have included gold salts, acupuncture, a diet consisting of apples or rhubarb, nutmeg, nettles, bee venom, bracelets made of copper, prayer, rest, tooth extractions, fasting, honey, vitamins, insulin, snow collected on Christmas, magnets, and electric convulsion therapy.

Did you know?

There used to be a metric calendar, as well as metric clocks. The metric calendar, or "French Republican Calendar" divided the year into 12 months, but each month was divided into three 10-day weeks. Each day had 10 decimal hours. Each hour had 100 decimal minutes. Due to lack of popularity, the metric clocks and calendars were ended in 1795, three years after they had been first marketed.

Did you know?

Anesthesia awareness is a potentially disturbing adverse effect wherein patients who have been paralyzed with muscle relaxants may awaken. They may be aware of their surroundings but unable to communicate or move. Neurologic monitoring equipment that helps to more closely check the patient's anesthesia stages is now available to avoid the occurrence of anesthesia awareness.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library